Is Aceminid a targeted drug? Belong to several generations

Asciminib (Asciminib) is a targeted drug and belongs to the third generation of targeted drugs. Aceminib is a small molecule inhibitor used to treat certain cancers, particularly those that are resistant to traditional chemotherapy drugs. It can directly act on targets within cancer cells and block intracellular signaling pathways, thereby inhibiting the growth and spread of tumor cells.

First of its kindThe STAMP (specifically targeting the myristoyl pocket of ABL) inhibitor acemini may be an effective and relatively safe option for patients with chronic myelogenous leukemia who are previously resistant to TKIs It is a potential treatment after previous studies have shown encouraging results in heavily pretreated patients with an acceptable toxicity profile. The findings based on the study demonstrate that aceminib therapy is also effective and safe in daily clinical practice in patients with chronic myelogenous leukemia who have failed multipleTKIs. Patients who switched to aceminib due to intolerance had higher response rates than patients who previously experienced TKI resistance, which is consistent with previous TKI studies.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminil sold overseas is very expensive, and the price of 20mg*60 oral tablets is about more than 20,000 US dollars (the price may fluctuate due to the exchange rate). There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.